Name: ELUTIA INC (ELUT) Stock
Brand: ELUTIA INC
Rating: 3 (3 reviews)

ELUT Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Benzinga - Mentions: NBY NEOG PMI APDN ...

12 Health Care Stocks Moving In Monday's After-Market Session

2 months ago - By: Elutia Inc.

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

2 months ago - By: Zacks Investment Research

Down 25.9% in 4 Weeks, Here's Why ELUTIA INC (ELUT) Looks Ripe for a Turnaround

3 months ago - By: Benzinga - Mentions: PACS PRPH ABP CYCN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

3 months ago - By: Elutia Inc.

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

3 months ago - By: The Motley Fool

Elutia Posts Narrower Loss in Fiscal Q2

8 months ago - By: Elutia Inc.

EluPro™ Named as 2025 Edison Award Winner

a month ago - By: Elutia Inc.

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

a month ago - By: Elutia Inc.

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

a month ago - By: Elutia Inc.

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

2 months ago - By: Elutia Inc.

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

3 months ago - By: Elutia Inc.

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

3 months ago - By: Zacks Investment Research

All You Need to Know About ELUTIA INC (ELUT) Rating Upgrade to Buy

3 months ago - By: Elutia Inc.

Elutia to Participate in Upcoming Investor Conferences

3 months ago - By: The Motley Fool

Elutia (ELUT) Q2 2025 Earnings Call Transcript

3 months ago - By: Elutia Inc.

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

4 months ago - By: Elutia Inc.

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award

5 months ago - By: Elutia Inc.

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices

6 months ago - By: Elutia Inc.

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

7 months ago - By: Elutia Inc.

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

7 months ago - By: Elutia Inc.

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

7 months ago - By: Elutia Inc.

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

7 months ago - By: Elutia Inc.

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

8 months ago - By: Elutia Inc.

Elutia to Participate in Upcoming Investor Conferences

8 months ago - By: Elutia Inc.

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

8 months ago - By: Elutia Inc.

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

9 months ago - By: Elutia Inc.

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

9 months ago - By: Elutia Inc.

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

10 months ago - By: Elutia Inc.

Elutia Announces $15.0 Million Registered Direct Offering

a year ago - By: Elutia Inc.

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

a year ago - By: Elutia Inc.

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

a year ago - By: Elutia Inc.

ELUTIA INC (ELUT) Stock News

ELUT Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Monday's After-Market Session

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

Down 25.9% in 4 Weeks, Here's Why ELUTIA INC (ELUT) Looks Ripe for a Turnaround

12 Health Care Stocks Moving In Tuesday's Intraday Session

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Elutia Posts Narrower Loss in Fiscal Q2

EluPro™ Named as 2025 Edison Award Winner

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

All You Need to Know About ELUTIA INC (ELUT) Rating Upgrade to Buy

Elutia to Participate in Upcoming Investor Conferences

Elutia (ELUT) Q2 2025 Earnings Call Transcript

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Elutia to Participate in Upcoming Investor Conferences

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Elutia Announces $15.0 Million Registered Direct Offering

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024